One question on affordable medicine, it's a generic businesses all put together. This year, you have done well with around 18% kind of growth. Just want to understand what's your outlook, let's say, for '27 and '28? What kind of the growth that you are looking at in this particular segment?
Is it possible to say that it can grow in the double -digit as well in the next year or it's like a single-digit growth?
One question on affordable medicine, it's a generic businesses all put together. This year, you have done well with around 18% kind of growth. Just want to understand what's your outlook, let's say, for '27 and '28? What kind of the growth that you are looking at in this particular segment?
Is it possible to say that it can grow in the double -digit as well in the next year or it's like a single-digit growth?
Kiran sir, just a question on GLP -1, right? In the recent call, you mentioned that you will be doing fragments like octamer, decamer, et cetera, right? Just want to understand that are these 2 fragments of a particular product that you're doing? Or there are multiple or all the fragments of a particular product that you are doing? Or is it just that these 2 fragments you are just showing as an example? Actually, I'm just trying to understand the scope of this opportunity, is it just limited to certain parts of the product? Or is it a larger one?
Understood. Just a related question, right? If you look at globally, especially in GLP -1, right, there are either players in China or there are players in Europe at this point of time. So how we see Divi's positioning, let's say, over the next 3 to 5 years down the line? And especially against the players in China like WuXi, right. So can Divi's reach to a scale what WuXi is doing today? Any qualitative comment would be helpful.